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A collection of genetically unrelated vancomycin-resistant enterococci (VRE) including 50 vanA, 15 vanB, 50
vanC1, and 30 vanC2 VRE were used to evaluate the accuracy of eight currently available susceptibility test
methods (agar dilution, disk diffusion, E-test, agar screen plate, Vitek GPS-TA and GPS-101, and MicroScan
overnight and rapid panels). vanA VRE were detected by all methods. vanB VRE were often not detected by
Vitek GPS-TA and MicroScan rapid (sensitivities, 47 and 53%, respectively), though the new Vitek GPS-101
was found to be a significant improvement. E-test and the agar screen were the only two methods detecting all
VRE, including the vanC1/C2 VRE.
The rapid increase in the incidence of infections with van-
comycin-resistant enterococci (VRE) in the western hemi-
sphere is reason for great concern (8). The Hospital Infection
Control Practices Advisory Committee recently published rec-
ommendations for preventing the spread of vancomycin resis-
tance (4). An important role is sought for the microbiology
laboratories as they, through accurate and timely detection of
resistance, are the first line of defense. To date, several studies
have been done assessing the accuracy of various antimicrobial
susceptibility methods in detecting vancomycin resistance in
enterococci (11–17). Since the occurrence of VRE is increasing
in the United States (1) and is likely to increase in Europe as
well, it is crucial to optimize the laboratory’s ability to detect
vancomycin resistance.
Three different genotypes (vanA, vanB, and vanD) have
been described that encode either high-, intermediate-, or low-
level acquired glycopeptide resistance, mainly in Enterococcus
faecium and Enterococcus faecalis (6). In addition, a fourth
genotype (vanC) has been found in Enterococcus gallinarum
and Enterococcus casseliflavus. This genotype encodes intrinsic,
low-level resistance to vancomycin but not to teicoplanin. An-
timicrobial susceptibility tests may have problems detecting the
low-level glycopeptide resistance phenotype (VanB or VanC).
To date, some reports have shown failure of several automated
susceptibility tests to detect vancomycin resistance (16, 17). In
response, the manufacturers of the Vitek system (BioMerieux,
Marcy l’Etoile, France) developed a new gram-positive suscep-
tibility card (GPS-101) and updated the software to overcome
this problem. Thus, the objective of this study was to evaluate
the accuracy of seven currently available commercial methods,
including the Vitek GPS-101 card, to detect VRE compared to
a reference agar dilution method (9). A collection of fully
characterized VRE strains, representing all the above-men-
tioned genotypes and phenotypes, was used in this study. One
hundred and ninety-five enterococci, including 50 vanA, 15
vanB, and 50 vanC1 VRE (E. gallinarum) and 30 vanC2 VRE
(E. casseliflavus) were isolated from patients or poultry prod-
ucts in Europe; the remaining 50 strains lacked these resis-
tance markers and were fully susceptible to vancomycin. Iden-
tification of Enterococcus spp. was made on the basis of
colonial morphology, pigment production, Gram stain, cata-
lase, pyrrolidonyl arylamidase, and Lancefield group D antigen
and by the API 32 rapid system. E. gallinarum was identified
upon digestion of DNA with SmaI and pulsed-field gel elec-
trophoresis showing all fragments to be ,200 kb and by the
presence of the vanC1 gene (3, 5). The test strains were care-
fully selected in order to maximize the variety of resistance
genotypes and phenotypes (16). Identical strains were ex-
cluded. All had unique pulsed-field gel electrophoresis pat-
terns and were, therefore, genetically unrelated (data not
shown). PCR assays for vanA, vanB, vanC1, and vanC2 genes
were performed as described by Dutka-Malen et al. (2). Agar
dilution and disk diffusion were performed in accordance with
the guidelines of the National Committee for Clinical Labora-
tory Standards (NCCLS) (9, 10) on cation-adjusted Mueller-
Hinton (MH) agar (Difco Laboratories, Detroit, Mich.). E-test
(AB Biodisk, Solna, Sweden) was done on MH agar in accor-
dance with the instructions of the manufacturer. The results
were read after a 24-h incubation at 37°C. An agar screen
containing 6 mg of vancomycin (BBL Microbiology Systems,
Cockeysville, Md.) per ml was used as described by Tenover et
al. (16) with an inoculum of 10 ml (approximately 106 CFU) of
a 0.5 McFarland standard suspension. The 30-well Vitek GPS-
TA, the 45-well Vitek GPS-101 with the updated GUI soft-
ware, MicroScan conventional overnight Pos Combo type 6
panels, and MicroScan Rapid Pos Combo type 1 panels with
V.20.30 software (Dade International, West Sacramento, Cal-
if.) were used as recommended by their respective manufac-
turers. E. faecalis ATCC 29212 and Staphylococcus aureus
ATCC 29213 were used as quality control strains. The NCCLS
breakpoints were used for interpretation of the results (9). A
very major error was defined as an isolate that was resistant by
the reference agar dilution method but susceptible with the
test method. A major error was defined as an isolate that was
susceptible by the reference agar dilution method but resistant
with the test method. Thus, lack of sensitivity of a given test
was deemed to be more serious clinically than lack of specific-
ity. A minor error was defined as a discrepancy between the
results of the reference agar dilution method and the test
method corresponding to one interpretation category. How-
ever, for the E. gallinarum and E. casseliflavus strains for which
MICs were 8 to 16 mg/ml, both intermediate- and resistant-
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phenotype results were considered correct, since both inter-
pretation categories correctly distinguish these vanC1- or
vanC2-harboring enterococci from fully susceptible strains
(MIC # 4 mg/ml). Similarly, sensitivity was defined as the
ability of the test method to correctly distinguish the vanA-,
vanB-, vanC1-, or vanC2-harboring resistant enterococci from
susceptible strains not harboring these genes. Therefore, for
strains with intermediate results with the reference agar dilu-
tion (MIC, 8 to 16 mg/ml), both intermediate- and resistant-
phenotype test results were considered correct.
The MICs of vancomycin with the reference agar dilution
method are shown by genotype in Table 1. Table 2 presents the
percentages of very major, major, and minor errors of the
different tests compared with the reference agar dilution
method. The comparative sensitivities of seven methods for the
detection of vanA, vanB, and vanC1/C2 VRE are shown in
Table 3. All methods were 100% sensitive for the detection of
vanA-mediated vancomycin resistance. However, it is impor-
tant to note that for all of the 50 vanA VRE MICs of vanco-
mycin were $256 mg/ml, and these strains were therefore de-
tected easily. For vanB VRE, the sensitivity dropped to 47, 53,
and 93% with Vitek GPS-TA, the MicroScan rapid panel, and
disk diffusion, respectively. In contrast, Vitek GPS-101, the
MicroScan conventional panel, the agar screen, and E-test
were 100% sensitive for detecting vanB VRE. For vanC1/C2
VRE, E-test and the agar screen were the only methods that
correctly identified all resistant strains as such. High error rates
were produced by disk diffusion and by all automated methods
(Table 2). The MicroScan conventional panel detected only
7% of the vanC2 E. casseliflavus. The sensitivities of the other
automated methods were 67 to 90% (Table 3). The specificities
of the different methods were 96 to 100%.
Earlier studies have reported on the performance of com-
mercial and reference methods for the detection of vancomy-
cin resistance in enterococci (11–17). Surprisingly, none of
these studies were performed in Europe. Some of the studies
reported on the difficulties of automated methods in detect-
ing low-level or intermediate-level vancomycin resistance (16,
17). In the study by Tenover et al., the performance of the
MicroScan rapid panel and the Vitek GPS-TA card were prob-
lematic, with very major error rates of 20.7 and 10.3%, respec-
tively. Many errors occurred with E. casseliflavus, E. gallina-
rum, and vanB VRE. We confirm the failure of these two
methods. The MicroScan rapid panel and Vitek GPS-TA had
33 and 40% very major errors with vanB strains, respectively
(Table 2). However, no very major errors occurred with the
MicroScan conventional panel or with Vitek GPS-101. No sus-
ceptible (vancomycin MIC # 4mg/l) E. gallinarum or E. cas-
seliflavus was found, possibly due to the fact that the strains
were initially isolated with the use of a selective broth medium
containing 6 mg of vancomycin per liter. Since for 78 of the 80
E. gallinarum and E. casseliflavus strains vancomycin MICs
were in the intermediate category (8 to 16 mg/ml), most errors
in these species were, by definition, minor errors. For one
vanC1 E. gallinarum strain and one vanC2 E. casseliflavus
strain, the MIC of vancomycin was 32 mg/ml. The latter strain
was incorrectly reported as susceptible by the MicroScan con-
ventional panel, and this result was scored as a very major
error (Table 2). The MicroScan conventional panel and Mi-
croScan rapid panel had 24 and 14% minor errors, respec-
tively, with vanC1 E. gallinarum but 90 and 10%, respectively,
with vanC2 E. casseliflavus. Vitek GPS-TA and Vitek GPS-101
had 28 and 12% minor errors, respectively, with vanC1 E.
gallinarum and 37 and 30%, respectively, with vanC2 E. cas-
seliflavus. The minor error rates of the disk diffusion with E.
gallinarum and E. casseliflavus were 50 and 37%, respectively.
Swenson et al. reported minor error rates of 14.5% of total
values. However, their collection of 100 VRE included only 10
E. gallinarum or E. casseliflavus isolates, and the most signifi-
cant errors in detection were in fact obtained mainly with these
strains (14). E-test and the agar screen were the only methods
TABLE 1. MH agar determination of MICs for 145 VRE
and 50 VSEa by genotype
Organism
(n)
No. of isolates for which the MIC (mg/ml) was:
0.25 0.5 1 2 4 8 16 32 64 128 $256
VRE
vanA (50) 50
vanB (15) 1 1 3 1 5 4
vanC1 (50) 30 19 1
vanC2 (30) 25 4 1
VSE (50) 1 6 32 9 2
a VSE, vancomycin-susceptible enterococci.
TABLE 2. Error rates of seven methods for detection of vancomycin resistance in enterococci
Method
Error rate (%)a
Very major
Major
(n 5 50)
Minor
vanA
(n 5 50)
vanB
(n 5 15)
vanC1
(n 5 50)
vanC2
(n 5 30)
vanA
(n 5 50)
vanB
(n 5 15)
vanC1
(n 5 50)
vanC2
(n 5 30)
E-test 0 0 0 0 0 0 13 2 0
Disk diffusion 0 0 0 0 2 0 27 50 37
Agar screen 0 0 0 0 4
MicroScan
Conventional 0 0 0 3 0 0 0 24 90
Rapid 0 33 0 0 0 0 27 14 10
Vitek
GPS-TA 0 40 0 0 4 0 13 28 37
GPS-101 0 0 0 0 4 2 7 12 30
a Relative to the NCCLS reference agar dilution assay. Error types are defined in the text.
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that correctly detected all VRE in our study. Light growth was
observed on the agar screen with two vancomycin-susceptible
strains (MIC, 4 mg/ml). This high sensitivity is in concordance
with recent data reported by Willey et al. (17). They found the
agar screen plate (using the same vancomycin concentration as
that used in our study) to be 100% sensitive and specific. In
another study, which included only a small number of strains
with MICs in the 8- to 16-mg/ml range, E-test proved to be a
reliable method compared to agar dilution (12).
The prevalence and the clinical relevance of E. casseliflavus
and E. gallinarum remain to be elucidated. These VRE are
often misidentified by commercial identification systems (data
not shown) (11), and their intermediate level of resistance may
not be detected. It is likely that these two species are being
underreported in the literature (7, 11).
In conclusion, vanA VRE are detected by all methods. vanB
VRE are often not detected by Vitek GPS-TA and the Mi-
croScan rapid panel, though the new Vitek GPS-101 appears
to be a significant improvement. All methods except E-test and
the agar screen continue to show problems in the detection of
vanC1/C2 VRE. The agar screen appears to be the most reli-
able and easy method for routine screening, if detection of
vanA-, vanB-, and vanC1/C2-mediated resistance in entero-
cocci is required. The new 45-well Vitek GPS-101 shows im-
proved sensitivity, compared to the Vitek GPS-TA, without
significant loss of specificity.
We gratefully acknowledge M. Humphrey for reading the English
version of the manuscript.
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TABLE 3. Sensitivities of seven methods for detection
of vanA, vanB, and vanC1/C2 enterococcia
Method
Sensitivity (%) for VRE
vanA
(n 5 50)
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(n 5 15)
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(n 5 50)
vanC2
(n 5 30)
E-test 100 100 100 100
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Conventional 100 100 76 7
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GPS-101 100 100 88 73
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intermediate- and resistant-phenotype results were considered correct.
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